William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

Benzinga Newsdesk www.benzinga.com Positive 69.7%

Neg 0% Neu 0% Pos 69.7%

William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating.

Comments

No comments yet. Be the first!